News | November 06, 2009

Avo Photonics, Case Western Develop OCT Forward Imaging Catheter for Ablations

November 6, 2009 – Nearly 4 million people nationwide suffer from cardiac arrhythmias each year, according to the 2006 U.S. Cardiac Rhythm Management Market report by Frost and Sullivan. About 2.5 million of these cases cannot be treated or controlled through medication alone. Since pharmacological therapies have limited effectiveness, radiofrequency (RF) catheter ablation has emerged as the prominent approach for treating a broad range of arrhythmias. However, during the procedure physicians have no direct visualization of intra-cardiac structures, nor do they have a means to measure successful lesions.

Recognizing this problem, researchers at Case Western Reserve University began a research program in 2008 to build an imaging catheter that would allow surgeons to monitor treatment and visualize intra-cardiac structures. The researchers selected Avo Photonics Inc., of Horsham, Pa., for a phase one design contract. The contract was awarded in September 2008. Avo’s rapid design effort provided a pathway for a subsequent October 2008 award for the development of prototype opto-mechanical systems. At the contract conclusion, Avo delivered eight forward imaging catheters to the university.

The forward imaging catheters (FIC) built by Avo will be used as monitors during RF cardiac arrhythmia therapy. These OCT catheters will lead to imaging techniques that will improve the insertion and accuracy of RF catheters, thus leading to better patient results and an expansion of approved FDA procedures for cardiac arrhythmia therapy.

Case Western Reserve University’s lead investigator on the project is Andrew Rollins, associate professor in the Department of Biomedical Engineering. Christine Fleming, a graduate research assistant under the advisement of Rollins, was instrumental in the design and development.

As a specialized opto-electronic engineering and manufacturing company, Avo provided critical resources and experience to the program. The Avo team was led by Program Manager Todd Rixman and Senior Optical Engineer David Demmer.

In May of 2009, Case Western Reserve imaged heart tissue through the Avo produced catheters.

This work was funded by under the Coulter-Case Translational Research Partnership.
For more information: www.avophotonics.com,

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init